Hepatitis C Virus Direct Acting Antivirals and Disruptive Innovation

Authors

  • S. Mantravadi University of West Florida
  • D. Snider University of West Florida

Keywords:

Sustainability, Innovation, Business, Pharmaceutical, Hepatitis, Market

Abstract

In 2011, a new wave of direct acting antiviral treatments to combat the hepatitis C virus entered the market. In this paper we discuss how the entrance of these pharmaceutical products fit the definition of a disruptive innovation along with how they affected patients, providers and insurers.

Downloads

Published

2017-12-01

How to Cite

Mantravadi, S., & Snider, D. (2017). Hepatitis C Virus Direct Acting Antivirals and Disruptive Innovation. Journal of Strategic Innovation and Sustainability, 12(2). Retrieved from https://articlearchives.co/index.php/JSIS/article/view/4746

Issue

Vol. 12 No. 2 (2017)

Section

Articles